Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine by Glatzer, Markus et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2021
Role of radiotherapy in the management of brain metastases of NSCLC –
Decision criteria in clinical routine
Glatzer, Markus ; Faivre-Finn, Corinne ; De Ruysscher, Dirk ; Widder, Joachim ; Van Houtte, Paul ;
Troost, Esther G C ; Slotman, Ben J ; Ramella, Sara ; Pöttgen, Christoph ; Peeters, Stephanie T H ;
Nestle, Ursula ; McDonald, Fiona ; Le Pechoux, Cecile ; Dziadziuszko, Rafal ; Belderbos, José ; Ricardi,
Umberto ; Manapov, Farkhad ; Lievens, Yolande ; Geets, Xavier ; Dieckmann, Karin ; Guckenberger,
Matthias ; Andratschke, Nicolaus ; Süveg, Krisztian ; Putora, Paul M
Abstract: Background Whole brain radiotherapy (WBRT) is a common treatment option for brain metas-
tases secondary to non-small cell lung cancer (NSCLC). Data from the QUARTZ trial suggest that WBRT
can be omitted in selected patients and treated with optimal supportive care alone. Nevertheless, WBRT
is still widely used to treat brain metastases secondary to NSCLC. We analysed decision criteria influenc-
ing the selection for WBRT among European radiation oncology experts. Methods Twenty-two European
radiation oncology experts in lung cancer as selected by the European Society for Therapeutic Radia-
tion Oncology (ESTRO) for previous projects and by the Advisory Committee on Radiation Oncology
Practice (ACROP) for lung cancer were asked to describe their strategies in the management of brain
metastases of NSCLC. Treatment strategies were subsequently converted into decision trees and anal-
ysed for agreement and discrepancies. Results Eight decision criteria (suitability for SRS, performance
status, symptoms, eligibility for targeted therapy, extra-cranial tumour control, age, prognostic scores
and “Zugzwang” (the compulsion to treat)) were identified. WBRT was recommended by a majority of
the European experts for symptomatic patients not suitable for radiosurgery or fractionated stereotactic
radiotherapy. There was also a tendency to use WBRT in the ALK/EGFR/ROS1 negative NSCLC set-
ting. Conclusion Despite the results of the QUARTZ trial WBRT is still widely used among European
radiation oncology experts.
DOI: https://doi.org/10.1016/j.radonc.2020.10.043
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-194303
Journal Article
Accepted Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Glatzer, Markus; Faivre-Finn, Corinne; De Ruysscher, Dirk; Widder, Joachim; Van Houtte, Paul; Troost,
Esther G C; Slotman, Ben J; Ramella, Sara; Pöttgen, Christoph; Peeters, Stephanie T H; Nestle, Ursula;
McDonald, Fiona; Le Pechoux, Cecile; Dziadziuszko, Rafal; Belderbos, José; Ricardi, Umberto; Manapov,
Farkhad; Lievens, Yolande; Geets, Xavier; Dieckmann, Karin; Guckenberger, Matthias; Andratschke,
Nicolaus; Süveg, Krisztian; Putora, Paul M (2021). Role of radiotherapy in the management of brain
metastases of NSCLC – Decision criteria in clinical routine. Radiotherapy and Oncology, 154:269-273.
DOI: https://doi.org/10.1016/j.radonc.2020.10.043
2
Journal Pre-proofs
Original Article
Role of radiotherapy in the management of brain metastases of NSCLC – De‐
cision criteria in clinical routine
Markus Glatzer, Corinne Faivre-Finn, Dirk De Ruysscher, Joachim Widder,
Paul Van Houtte, Esther G.C. Troost, Ben J. Slotman, Sara Ramella,
Christoph Pöttgen, Stephanie T.H. Peeters, Ursula Nestle, Fiona McDonald,
Cecile Le Pechoux, Rafal Dziadziuszko, José Belderbos, Umberto Ricardi,
Farkhad Manapov, Yolande Lievens, Xavier Geets, Karin Dieckmann,
Matthias Guckenberger, Nicolaus Andratschke, Krisztian Süveg, Paul M.
Putora
PII: S0167-8140(20)30892-6
DOI: https://doi.org/10.1016/j.radonc.2020.10.043
Reference: RADION 8611
To appear in: Radiotherapy and Oncology
Received Date: 2 October 2020
Revised Date: 27 October 2020
Accepted Date: 31 October 2020
Please cite this article as: Glatzer, M., Faivre-Finn, C., De Ruysscher, D., Widder, J., Van Houtte, P., Troost,
E.G.C., Slotman, B.J., Ramella, S., Pöttgen, C., Peeters, S.T.H., Nestle, U., McDonald, F., Le Pechoux, C.,
Dziadziuszko, R., Belderbos, J., Ricardi, U., Manapov, F., Lievens, Y., Geets, X., Dieckmann, K., Guckenberger,
M., Andratschke, N., Süveg, K., Putora, P.M., Role of radiotherapy in the management of brain metastases of
NSCLC – Decision criteria in clinical routine, Radiotherapy and Oncology (2020), doi: https://doi.org/10.1016/
j.radonc.2020.10.043
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover
page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version
will undergo additional copyediting, typesetting and review before it is published in its final form, but we are
providing this version to give early visibility of the article. Please note that, during the production process, errors
may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in 
clinical routine 
Markus Glatzer1, Corinne Faivre-Finn2, Dirk De Ruysscher3, Joachim Widder4, Paul Van Houtte5, Esther 
G.C. Troost6-10, Ben J. Slotman11, Sara Ramella12, Christoph Pöttgen13, Stephanie T.H. Peeters3, Ursula 
Nestle14,15, Fiona McDonald16, Cecile Le Pechoux17, Rafal Dziadziuszko18, José Belderbos19, Umberto 
Ricardi20, Farkhad Manapov21, Yolande Lievens22, Xavier Geets23, Karin Dieckmann4, Matthias 
Guckenberger24, Nicolaus Andratschke24, Krisztian Süveg1, Paul M. Putora1,25 
 
1 Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland 
2 Division of Cancer Sciences, University of Manchester & The Christie NHS Foundation Trust Manchester, Manchester, UK. 
3 Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), 
Maastricht, The Netherlands 
4 Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria 
5 Department of Radiation Oncology, Institut Bordet, Université Libre Bruxelles, Belgium 
6 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 
Dresden, Germany. 
7 Institute of Radiooncology - OncoRay Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany. 
8 OncoRay, National Center for Radiation Research in Oncology, Dresden, Germany. 
9 German Cancer Consortium (DKTK), partnersite Dresden, Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 
10 National Center for Tumour Diseases (NCT), Partner Site Dresden, Dresden, Germany. 
11 Department of Radiation Oncology, Amsterdam University Medical Center, VUMC, Amsterdam, The Netherlands 
12 Department of Radiation Oncology, Campus Bio-Medico University, Rome, Italy 
13 Department of Radiation Oncology, West German Tumor Centre, University of Duisburg-Essen Medical School, Germany 
14 Department of Radiation Oncology, Kliniken Maria Hilf, Moenchengladbach, Germany 
15 Department of Radiation Oncology, University Hospital Freiburg, Germany 
16 Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK 
17 Departement Oncologie Radiotherapie, Gustave Roussy, Villejuif, France 
18 Department of Oncology and Radiotherapy, Gdansk, Poland 
19 Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands 
20 Department of Oncology, University of Turin, Via Genova 3, 10126, Turin, Italy 
21 Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, Munich, Germany 
22 Radiation Oncology Department, Ghent University Hospital and Ghent University, Ghent, Belgium  
23 Department of Radiation Oncology, Cliniques universitaires Saint-Luc, MIRO - IREC Lab, UCL, Belgium. 
24 Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 
25 Department of Radiation Oncology, University of Bern, Bern, Switzerland 
 
 
 
 
Corresponding Author:  
Dr.med.univ. Markus Glatzer 
Department of Radiation Oncology, Kantonsspital St.Gallen  
CH-9007 St.Gallen, Switzerland 
Markus.glatzer@kssg.ch 
 
  
 
Abstract 
Background: Whole brain radiotherapy (WBRT) is a common treatment option for brain metastases 
secondary to non-small cell lung cancer (NSCLC). Data from the QUARTZ trial suggest that WBRT can 
be omitted in selected patients and treated with optimal supportive care alone. Nevertheless, WBRT 
is still widely used to treat brain metastases secondary to NSCLC. We analysed decision criteria 
influencing the selection for WBRT among European radiation oncology experts. Methods: 22 
European radiation oncologist experts in lung cancer as selected by the European Society for 
Therapeutic Radiation Oncology (ESTRO) for previous projects and by the Advisory Committee on 
Radiation Oncology Practice (ACROP) were asked to describe their strategies in the management of 
brain metastases of NSCLC. Treatment strategies were subsequently converted into decision trees and 
analysed for agreement and discrepancies. Results: 9 decision criteria (suitability for SRS, performance 
status, symptoms, eligibility for targeted therapy, extra-cranial tumour control, age, prognostic scores 
and “Zugzwang” (the compulsion to treat)) were identified. WBRT was recommended by a majority of 
the European experts for symptomatic patients not suitable for radiosurgery or fractionated 
stereotactic radiotherapy. There was also a tendency to use WBRT in the ALK/EGFR/ROS1 negative 
NSCLC setting. Conclusion: Despite the results of the QUARTZ trial WBRT is still widely used among 
European radiation oncologist experts.    
Introduction 
Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) 
accounts for approximately 85% of all lung cancers (1). 10% of patients with NSCLC have brain 
metastases at diagnosis, and 25%–40% develop brain metastases during their disease (2). Approaches 
in the management of brain metastases include surgery, stereotactic radiosurgery (SRS), fractionated 
stereotactic radiotherapy, whole brain radiation therapy (WBRT), systemic treatments or best 
supportive care alone (3). The choice of treatment depends on various factors such as the number and  
volume of brain metastases, control of the extracranial disease, performance status or tumour biology 
(e.g. EGFR gene mutation) (4).  
While the use of stereotactic radiosurgery in patients with limited volume of brain metastases has 
been well defined, its role in patients with multiple lesions is still a matter of debate. WBRT is a 
treatment of choice for patients with multiple brain lesions and is still the most commonly used 
treatment approach worldwide (5). The randomized QUARTZ trial investigated the use of 
dexamethasone and optimal supportive care (OSC) with or without whole brain irradiation in patients 
with NSCLC and brain metastases unsuitable for stereotactic radiotherapy. The primary endpoint of 
this non-inferiority trial was quality-adjusted life-years (QALYs). The study randomised 538 patients 
across UK and Australia.  QALYs in the supportive care plus WBRT group were 46.4 days compared to 
41.7 days in the group receiving supportive care alone. Overall survival in both groups was similar (HR 
1.06, 95% CI 0.90-1.26, p=0.81) with a median survival for patients with WBRT of 9.2 weeks and 8.5 
weeks for those treated with supportive care alone. Quality of life was similar between groups. 
Subgroup analyses showed a significant effect in favour of WBRT in the subgroup <60 years (p=0.0062) 
while no significant effect of WBRT was observed in other subgroups (stratified according to gender, 
Karnofsky Performance Status, disease control, presence of extra-cranial metastases) (6). WBRT could 
therefore be omitted in most patients and optimal supportive care alone seems to be as effective. The 
study was performed before the era of routine molecular testing in NSCLC.  
In clinical routine many criteria influence the decision-making process. The aim of this study was to 
identify relevant criteria in the complex process of patient selection and decision-making for the 
management of patients with brain metastases from NSCLC. As there are different ways of performing 
WBRT (different dose schedules and different techniques) prescribed dose and the use of hippocampal 
avoidance (HA) were also evaluated. 
Methods 
We asked 22 radiation oncologists who were identified by the European Society for Radiatiotherapy 
and Oncology (ESTRO) and by the Advisory Committee on Radiation Oncology Practice (ACROP) as 
experts in the field of lung cancer to participate in this analysis. Each expert was asked the following 
question: „Please describe if and for which patients with NSCLC you would recommend WBRT. Please 
describe any criteria used in your decision-making.” As there are various dose schedules and the option 
to avoid the hippocampal region (HA) we also asked the experts to provide their answer to the 
following question: „ Please describe your dose, technique and whether you use HA.” Answers were 
allowed in any format (e.g. free text, tables, diagrams or figures). No specific clinical scenarios, 
examples or decision criteria were proposed in order to avoid influencing responses. After the initial 
collection of all responses, treatment strategies were converted into decision trees, and decision 
criteria were extracted (7). To enable cross-comparison of algorithms, compatible criteria are a 
prerequisite. Similar decision criteria were fused into new comprehensive categories. For example, 
criteria such as fast progression of brain metastases, progression of brain metastases only under 
systemic treatment, high tumour load in the brain, or brain metastases near critical structures 
(brainstem, chiasma, optic nerves) were summarised as criteria which might lead to the compulsion to 
treat in a timely manner, named “Zugzwang”, a German word first implemented in this setting in 2015 
in a decision-making analysis for renal cell carcinoma (8). Decision criteria only mentioned by four or 
less experts (insular criteria) were not included into the decision trees for better overview (9). Age is 
one example. Age was only mentioned by three radiation oncologists as a criterion relevant for 
decision-making and recommended WBRT only for younger patients (age <60-70 years). Another 
factor only used by very few experts for decision-making was a prognostic score (like RPA or GPA). It 
was explicitly mentioned by four experts, thus this factor was also not included in the final decision 
trees. 
Consensus and discrepancies were evaluated with the objective consensus methodology as previously 
described (7, 10, 11). When 14 or more of the experts (>60%) recommended the same we defined it 
as consensus.   
 
Results 
22 experts provided their decision-making and treatment strategies.  
Radiation doses used for WBRT were 30Gy in 10 fractions, 20Gy in 5 fractions or 12x2.5Gy/4.25Gy 
(simultaneous integrated boost (SIB)) as used in the phase II HIPPORAD trial (12). Most of the experts 
(17 out of 22, 77%) used the 10x3Gy fractionation regimen in daily routine. Eight radiation oncologists 
(36%) always used 10x3Gy for WBRT, 6 (27%) preferred 10x3Gy but for patients with reduced 
performance status or for patients who would need to start systemic treatments promptly they also 
offered 5x4Gy. Three centres (14%) treated brain metastases within the HIPPORAD trial (a prospective, 
randomized, two-arm phase II multicentre trial comparing the impact of HA on neurocognitive failure 
after HA-WBRT+SIB versus WBRT+SIB in patients with multiple brain metastases) or analogous to this 
trial (12). For patients not qualifying for the HIPPORAD trial two of the experts (9%) used WBRT with 
10x3Gy instead, and one radiation oncologist (4%) offered 10x3Gy or 5x4Gy depending on 
performance status. 5 out of our 22 experts always recommended 5x4Gy for WBRT.  
The preferred technique for WBRT was a standard 3D technique with opposing fields +/- field in field 
technique. HA-WBRT or WBRT with SIB was performed either using helical IMRT with Tomotherapy or 
VMAT. Seven experts (32%) offered HA in clinical routine outside of trials. Among these experts, 2 
always performed HA-WBRT when WBRT was performed, 3 experts recommended HA only for very fit 
patients with a relatively long life expectancy with good systemic treatment options and a limited 
number of brain metastases, and 2 radiation oncologists used HA-WBRT only in the re-irradiation 
setting for progressive disease in the brain after stereotactic radiotherapy. A contraindication for HA-
WBRT in all centres offering it, was the location of brain metastases near the hippocampus.     
The decision criteria used for the management of brain metastases in NSCLC included: suitability for 
SRS, performance status, symptoms, eligibility for targeted therapy (ALK+, EGFR+ or ROS1+ tumour 
profiles or PDL1 expression), extra-cranial tumour control (present or achievable), age, prognostic 
scores and “Zugzwang” (the compulsion to treat (8)) (Table 1). Suitability for SRS was defined very 
heterogeneously among experts. One expert performed SRS in patients with up to 15 brain metastases, 
4 experts recommended SRS for up to 10 metastases, for 3 experts the cut-off was 5 metastases, 6 
experts recommended SRS in patients with 4 or less metastases and 3 experts only performed SRS in 
case of 3 or less metastases. In summary, more than 70% of the experts who used the number of brain 
metastases for decision-making, would do SRS only in patients with up to 5 brain metastases (Figure 
1). While the majority of experts (77%) used the number of brain metastases for decision-making, for 
5 experts the cumulative volume of brain metastases (e.g. <20 cm3) was more crucial. However, in 
case of a limited number or volume of brain metastases all experts recommended a local treatment, 
either SRS, fractionated stereotactic radiotherapy or surgery. A worse performance status, defined as 
Karnofsky Performance Status (KPS) <70 by the majority of our experts, was a contraindication for 
radiotherapy to the brain. One expert defined “worse” performance status as KPS of ≤50. 
 age volume/number 
of brain 
metastases 
prognostic 
scores  
extracranial 
control 
PS eligibility for 
targeted 
therapy 
symptoms                               «Zugzwang» 
critical 
location  
critical 
size  
fast 
progression 
pressure 
of the 
referring 
physicians 
A x x x x x x  x    
B  x   x  x x   x 
C  x   x x x    x 
D  x  x x         
E  x   x x x   x  
F x x  x x x x      
G  x x  x x      
H  x x x x x      
I  x   x       
Table 1. Decision criteria implemented per center (A-V); PS – performance status  
 
 
Figure 1. Definition of “suitability for SRS” by the experts. The more brain metastases the less experts recommended stereotactic 
radiosurgery. In up to 3 metastases, all experts considered SRS, for one expert (6%) SRS was recommended for up to 15 brain metastases.  
 
The majority of participating radiation oncologists recommended WBRT for symptomatic brain 
metastases when targeted therapies like TKI or immuno-oncology agents were not an option, 
regardless of extra-cranial tumour control (Figure 2). Two experts explicitly mentioned that they would 
perform WBRT only after improvement of symptoms after initiation of corticosteroids. In patients who 
are candidates for targeted therapies (ALK+, EGFR+, ROS1+ or PDL1 expression) 64% of experts would 
prefer starting with targeted therapy, e.g. TKI alone, and only when metastases in the brain progress 
(“Zugzwang”) they would recommend WBRT. For asymptomatic patients the trend for WBRT 
decreases. Most of the experts avoid WBRT in asymptomatic patients with driver mutation positive 
tumours, except if the tumour progresses in the brain under systemic therapy. For 32% of our experts 
the location of brain metastases near critical structures in the brain, very large metastases or a fast 
100%
82%
47%
29%
6%
3 metastases 4 metastases 5 metastases 10 metastases  15 metastases
experts (%)
J  x   x  x     
K  x  x x   x     
L  x   x x x     
M  x   x       
N x x   x  x     
O  x  x x     x  
P  x   x x x     
Q  x x x x  x   x  
R  x   x       
S  x   x  x x x x  
T  x   x x  x x   
U  x   x       
V  x   x       
progression of brain metastases (summarized as Zugzwang) was an indication for WBRT even if 
effective systemic treatment options were available.  
 
Figure 2. Consensus for WBRT/noWBRT. No consensus = 13 or less experts (<60%). BRA – Brain, Zugzwang - the compulsion to treat.   
 
Discussion 
For a limited number and/or volume of brain metastases a focal therapy (surgery, radiosurgery, and 
fractionated radiotherapy) seems to be the treatment of choice as highlighted by our analysis. All of 
our experts recommend a local treatment for limited brain metastases. The definition of “limited” 
varies among the experts, and in literature, where no universally accepted definition exists (13). For 
most of our experts “limited” was defined as 4 or less brain metastases.  When metastases cannot 
reasonably be treated with local treatments, WBRT is a treatment option. This decision-making 
analysis shows that WBRT is still widely used, especially for symptomatic patients. However, the use 
of WBRT in the management of brain metastases of NSCLC decreases. This is mainly due to more 
effective drugs, e.g. targeted therapies, but also due to improved radiation techniques allowing for a 
better sparing of macroscopically unaffected brain tissue. The data of the QUARTZ trial for patients 
that were not candidates for SRS, demonstrating no significant QALY benefit for WBRT compared to 
OSC alone, must also play a role in the decision making process (6). Some subgroups of patients, e.g. 
patients with good KPS (≥70%) and age<60, in general patients with good prognostic scores (e.g. RPA 
or GPA score) derived more clinical benefit from WBRT. Age was only used by 3 of our experts and the 
use of a score (GPA and/or RPA) was explicitly mentioned by 4 experts as decision-making criterion. All 
experts included KPS/PS in their decision-making analysis and a poor performance status was a 
contraindication for WBRT for all of our experts. The main selection criterion for patients in the 
QUARTZ trial was the uncertainty in the clinicians’ or patients’ minds about the potential benefit of 
WBRT. This resulted in a very unfavourable selection of NSCLC patients with a high proportion of 
patients with uncontrolled primary and extracranial metastases, overall, patients with a poor 
prognosis. Thus, it seems these criteria are closely considered in clinical routine. In our analyses, more 
than half of the experts did so. Most of the experts in our analysis used extra-cranial disease control 
and also the eligibility for targeted therapy for their decision-making. Especially for controlled 
extracranial disease most of our experts recommended WBRT in patients unsuitable for SRS, as 
patients with favourable prognosis benefit from WBRT. This is in-line with published literature:Agarwal 
et al (14) investigated prognostic factors to identify patients with poor prognosis who may not benefit 
from WBRT and translated the factors into a prognostic model. They mentioned EGFR mutation, KPS 
and gender as significant prognostic factors of overall survival. Patients with poor performance status, 
male gender or EGFR wildtype NSCLC had a median overall survival of 67 days and therefore may not 
benefit from WBRT.  
Another limitation of the QUARTZ trial is that most patients did not receive systemic therapy.  As many 
targeted therapies (e.g. for EGFR-mutant or ALK positive lung cancers) have a good CNS penetration 
with more than 70% intracranial response rate (15), there is a trend for omission of  WBRT, especially  
in patients with NSCLC and suitable for targeted agents. This was highlighted in this analysis as some 
of our experts only recommend WBRT in patients who are not eligible for targeted therapy. In the past 
decade new targeted therapies and immunotherapies for patients with NSCLC changed the treatment 
approaches and outcome of patients with brain metastases considerably.  
Molecular characteristics and KPS/PS were also identified in our analysis as factors used by our experts 
for their decision-making process.  
Interestingly, some of our experts also used tumor growth or the location of the brain metastases for 
decision-making. While the static situation of the tumor might fulfill the criterion to rather defensive 
or passive approach, clinicians identify factors such as fast growth or critical location as a compulsion 
to treat actively (Zugzwang). Next to commonly used decision-criteria (as used in clinical trials and 
databases), the concept of Zugzwang allowed for a representation of a certain urgency which is 
commonly interpreted by the clinician.  
The variability of decision criteria among the participating experts may have multiple causes. These 
may include local traditions, level of individual experience as well as different guidelines used for 
development of local recommendation of the interdisciplinary tumour board. The aim of this study 
was to assess criteria in the complex process of patient selection for the management of brain 
metastases in NSCLC patients.  This survey is only a surrogate and should give an impression on which 
criteria are used and which treatment decision are made. The clinical decision-making process is rarely 
a 1:1 extraction from published data, this is why we believe this work adds to the understanding of 
how literature is applied to clinical practice. 
The prescribed radiation doses for WBRT in this analysis included 10x3Gy, 5x4Gy or dose regimens 
with SIB. Current guidelines (16, 17) recommend WBRT dose schemes of 20 - 40Gy in 5–20 fractions. 
The most frequent WBRT schedules are 20Gy in 5 fractions or 30 Gy in 10 fractions, with no difference 
in outcome (18). The most common fractionation regime used by experts in our study was 30 Gy in 10 
fractions or 20 Gy in 5 fractions, for patients with reduced performance status. Very few experts 
treated brain metastases within or accordingly to the ongoing randomized phase II HIPPORAD trial 
(12). The aim of this trial is to assess the efficacy and safety of WBRT with HA combined with a SIB to 
metastases/resection cavities. Much of the concern over WBRT relates to associated toxicities which 
include cognitive deficits (19). Radiation dose to the neuro-regenerative zone of the hippocampus 
seems to be associated with cognitive decline. Hippocampal avoidance is hypothesized to preserve 
cognition. The recently published randomized study by Brown et al (20) showed better preservation of 
cognitive function and patient-reported symptoms, with no difference in intracranial PFS and OS, when 
using HA-WBRT and concurrent memantine compared to WBRT and memantine in patients with brain 
metastases. As only in 2% of patients metastases will appear in the hippocampus and up to 8% in the 
perihippocampal area, the approach of HA should be considered as a treatement option (21). However, 
as there are other data showing no significant difference in neurocognition between HA WBRT 
compared to standard WBRT (22), HA is not universally accepted. This is also conveyed in this analysis 
as two thirds of experts to do not use HA-WBRT in clinical routine. However, there are various trials in 
progress.    
In summary, WBRT is still widely used among European thoracic radiation oncology experts with a 
trend towards the use of WBRT for symptomatic brain metastases who cannot be treated with 
stereotactic radiotherapy. 10x3Gy was the most commonly used fractionation regimen among the 
experts. For patients with asymptomatic brain metastases and suitable for targeted therapies, the 
majority of our lung cancer experts recommended a watchful waiting strategy with regards to 
radiotherapy treatment.  
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Highlights 
1. WBRT is still widely used among European radiation oncology experts with a trend towards 
the use of WBRT for symptomatic brain metastases and contraindication for stereotactic 
radiotherapy. 
 
2. For patients with asymptomatic brain metastases and option for targeted therapies, a 
watchful waiting strategy with regards to radiotherapy treatment is a common strategy 
among European experts. 
 
 
3. WBRT with 10x3Gy was the most commonly used fractionation regimen among the experts. 
 
 
 
